Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.59 |
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | PRKDC | P78527 | 3/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.56 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.51 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.51 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.51 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23150470 | 0.91 | MTOR (0.76) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL23251837 | 0.89 | MTOR (0.61) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL24519414 | 0.87 | MTOR (0.59) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL25678264 | 0.86 | MTOR (0.66) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL21528221 | 0.86 | MTOR (0.66) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL30404651 | 0.86 | MTOR (0.66) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL23251730 | 0.86 | MTOR (0.58) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL23251706 | 0.85 | MTOR (0.58) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL23251749 | 0.85 | MTOR (0.58) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL28518632 | 0.85 | MTOR (0.65) | MTORHDAC1HDAC8HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3788049-B1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-02-23 | — | — | US | disclosed |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-11-04 | — | — | US | disclosed |
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3788050-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3788049-A1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | Revolution Medicines, Inc. | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885HDAC1 695/4885HDAC8 725/4885 |
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885HDAC1 526/4885HDAC8 142/4885 |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885HDAC1 526/4885HDAC8 142/4885 |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885HDAC1 526/4885HDAC8 142/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | MTOR 1/4885HDAC1 695/4885HDAC8 725/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | MTOR 3/4885HDAC1 392/4885HDAC8 403/4885 |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885HDAC1 526/4885HDAC8 142/4885 |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885HDAC1 526/4885HDAC8 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.